Cover Image

Economic burden of patients with leading cancers in China: a cost-of-illness study

China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Wu, Ziting (Author) , Yu, Yiwen (Author) , Xie, Feng (Author) , Chen, Qiushi (Author) , Cao, Zhong (Author) , Chen, Simiao (Author) , Liu, Gordon G. (Author)
Format: Article (Journal)
Language:English
Published: 27 September 2024
In: BMC health services research
Year: 2024, Volume: 24, Pages: 1-13
ISSN:1472-6963
DOI:10.1186/s12913-024-11514-x
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s12913-024-11514-x
Verlag, kostenfrei, Volltext: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-024-11514-x
Get full text
Author Notes:Ziting Wu, Yiwen Yu, Feng Xie, Qiushi Chen, Zhong Cao, Simiao Chen and Gordon G. Liu
Description
Summary:China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China.
Item Description:Gesehen am 17.06.2025
Physical Description:Online Resource
ISSN:1472-6963
DOI:10.1186/s12913-024-11514-x

Similar Items